These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 27307107)

  • 1. Systemic lupus erythematosus: still a challenge for physicians.
    Bengtsson AA; Rönnblom L
    J Intern Med; 2017 Jan; 281(1):52-64. PubMed ID: 27307107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
    Espinosa G; Cervera R
    Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Treatments in Lupus.
    Kyttaris VC
    Curr Rheumatol Rep; 2017 Mar; 19(3):10. PubMed ID: 28265845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belimumab for systemic lupus erythematosus: a practice-based view.
    Parodis I; Axelsson M; Gunnarsson I
    Lupus; 2013 Apr; 22(4):372-80. PubMed ID: 23553780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting BLyS in systemic lupus erythematosus.
    Liu Y; La Cava A
    Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):91-6. PubMed ID: 22216778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the BLyS-APRIL signaling pathway in SLE.
    La Cava A
    Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
    Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
    Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Belimumab therapy in systemic lupus erythematosus.
    Zouali M; Uy EA
    BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.
    Sthoeger Z; Sharabi A; Mozes E
    J Autoimmun; 2014 Nov; 54():60-71. PubMed ID: 24958634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
    Poh YJ; Baptista B; D'Cruz DP
    Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of Clinical Trials of Belimumab in the Management of Systemic Lupus Erythematosus.
    Garcia A; De Sanctis JB
    Curr Pharm Des; 2016; 22(41):6306-6312. PubMed ID: 27587201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B cell alterations during BAFF inhibition with belimumab in SLE.
    Ramsköld D; Parodis I; Lakshmikanth T; Sippl N; Khademi M; Chen Y; Zickert A; Mikeš J; Achour A; Amara K; Piehl F; Brodin P; Gunnarsson I; Malmström V
    EBioMedicine; 2019 Feb; 40():517-527. PubMed ID: 30593436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous belimumab in the treatment of systemic lupus erythematosus.
    Elalouf O; Keeling SO; Touma Z
    Immunotherapy; 2018 Sep; 10(13):1163-1173. PubMed ID: 30105936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recommendations on the use of belimumab in systemic lupus erythematosus. GEAS-SEMI Clinical Practice Guide].
    Ramos-Casals M; Ruiz-Irastorza G; Jiménez-Alonso J; Khamashta MA;
    Rev Clin Esp (Barc); 2013; 213(1):42-58. PubMed ID: 23266125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Belimumab: targeted therapy for lupus.
    Chugh PK; Kalra BS
    Int J Rheum Dis; 2013 Feb; 16(1):4-13. PubMed ID: 23441766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.